T
Tai Wong
Publications - 4
Citations - 658
Tai Wong is an academic researcher. The author has contributed to research in topics: Clear cell renal cell carcinoma & Cancer. The author has an hindex of 3, co-authored 4 publications receiving 457 citations.
Papers
More filters
Journal ArticleDOI
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen,Haley Hill,Alana Christie,Min Kim,Eboni Holloman,Andrea Pavia-Jimenez,Farrah Homayoun,Yuanqing Ma,Nirav V. Patel,Paul Yell,Guiyang Hao,Qurratulain Yousuf,Allison Joyce,Ivan Pedrosa,Heather Geiger,He Zhang,Jenny Chang,Kevin H. Gardner,Richard K. Bruick,Catherine Reeves,Tae Hyun Hwang,Kevin D. Courtney,Eugene P. Frenkel,Xiankai Sun,Naseem J. Zojwalla,Tai Wong,James P. Rizzi,Wallace Eli M,John A. Josey,Yang Xie,Xian Jin Xie,Payal Kapur,Renée M. McKay,James Brugarolas +33 more
TL;DR: It is shown that some ccRCCs are HIF-2 independent, and set the stage for biomarker-driven clinical trials, using a tumourgraft/patient-derived xenograft platform to evaluate PT2399, a selective Hif-2 antagonist that was identified using a structure-based design approach.
Journal ArticleDOI
3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma.
Rui Xu,Keshi Wang,James P. Rizzi,Heli Huang,Jonas Grina,Stephen T. Schlachter,Bin Wang,Paul M. Wehn,Hanbiao Yang,Darryl D. Dixon,Robert M. Czerwinski,Xinlin Du,Emily L Ged,Guangzhou Han,Huiling Tan,Tai Wong,Shanhai Xie,John A. Josey,Eli M. Wallace +18 more
TL;DR: The discovery of second-generation HIF-2α inhibitor PT2977 is described with increased potency and improved pharmacokinetic profile achieved by reduction of phase 2 metabolism, which supports the hypothesis that attenuating the rate of glucuronidation would improve exposure and reduce variability in patients.
Journal ArticleDOI
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385)
Paul M. Wehn,James P. Rizzi,Darryl D. Dixon,Jonas Grina,Stephen T. Schlachter,Bin Wang,Rui Xu,Hanbiao Yang,Xinlin Du,Guangzhou Han,Keshi Wang,Zhaodan Cao,Tzuling Cheng,Robert M. Czerwinski,Barry Goggin,Heli Huang,Megan M. Halfmann,Melissa A. Maddie,Emily L. Morton,Sarah R. Olive,Huiling Tan,Shanhai Xie,Tai Wong,John A. Josey,Eli M. Wallace +24 more
TL;DR: Evaluation of select compounds from two structural classes in a sequence of PK/PD, efficacy, PK, and metabolite profiling identified 10i (PT2385, luciferase EC50 = 27 nM) as the clinical candidate.
Patent
Methods of reducing inflammation of the digestive system with inhibitors of hif-2-alpha
TL;DR: In this article, the authors provide methods of reducing inflammation of the digestive system in a subject in need thereof, including subjects suffering from inflammatory bowel disease, and compositions for use in these methods are also provided.